Please login to the form below

Not currently logged in
Email:
Password:

J&J increases holding in Chinese joint venture

According to a company insider, Johnson & Johnson China Investment will buy further shares in Xi'an-Janssen Pharmaceutical

According to an insider, Johnson & Johnson China Investment, a 100-owned subsidiary of US-based Johnson & Johnson (J&J) will buy further shares in Xi'an-Janssen Pharmaceutical from shareholders in the Chinese company.

The financial website TradingMarkets said that the information was leaked from an employee of the pharmaceutical joint venture on 20 November 2007.

J&J is said to be in negotiations with three Chinese shareholders to acquire a 17.2 per cent stake on the basis that the equity structure of the sellers would not change. The acquisition has been approved by China's Ministry of Commerce, according to the insider.

The deal could extend J&J's control in Xi'an-Janssen from 52 to 70 per cent.

J& J China Investment recently acquired 1.8 per cent of Xi'an-Janssen for CNY 78m (approx. USD 10.5m) from Shaanxi Hanjiang Pharmaceutical Group. The other three Chinese shareholders are Shaanxi Pharmaceutical Industry (33.6 per cent), China National Pharmaceutical Industry (5.8 per cent) and China National Pharmaceutical Foreign Trade (3.8 per cent).

Xi'an-Janssen was jointly set up by J&J's subsidiary Belgium-based Janssen Pharmaceutica and the above four Chinese state-owned companies in October 1985.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics